Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data BridgeBio Pharma, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
40.6
8.25
69.7
77.6
9.3
222
502
Cost of revenue
3.11
3.43
2.45
3.88
21
Gross profit
66.6
74.2
6.86
218
481
Research and development
30.6
140
210
337
451
399
456
506
452
Selling, general and administrative
94.4
146
192
143
151
289
531
General and administrative
13.3
43.6
94.4
146
Operating expenses
43.9
184
307
483
Operating income
-43.9
-184
-266
-474
-577
-512
-607
-593
-523
Interest expense
0.01
2.55
8.77
36.7
46.8
80.4
81.3
91
53.1
Interest income
0.04
2
8.92
4.02
1.13
7.54
18
17.2
19.9
Other non-operating income
0.03
14.2
-22.3
-31
-9.82
27.6
-45.9
50.8
-209
Pre-tax income
43.8
169
289
505
-586
-485
-653
-542
-733
Income tax
0
0
1.15
0.44
Net income to minority interests
-13.3
-38.7
-28
-56.8
-23.9
-3.47
-10
-7.59
-8.01
Net income
-30.6
-131
-261
-449
-563
-481
-643
-536
-725
EBITDA
-265
-473
-571
-505
-601
-587
-518
EPS, basic
-1.00
-2.12
-2.48
-3.80
-3.90
-3.26
-3.95
-2.88
-3.78
EPS, diluted
-1.00
-2.12
-2.48
-3.80
-3.90
-3.26
-3.95
-2.88
-3.78
Shares, basic (weighted)
30.6
61.8
105
118
144
147
163
186
192
Shares, diluted (weighted)
30.6
61.8
105
118
144
147
163
186
192
Balance sheet
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
92
436
364
356
394
377
376
681
570
Short-term investments
182
251
394
51.6
0
0
17.4
Receivables
1.75
4.72
139
Inventory
0
26.8
Other current assets
2.05
19.8
35.7
32.3
21.9
24.3
34.9
44.1
Total current assets
445
569
643
889
549
478
721
798
Property, plant and equipment
1.58
5.63
20.3
30.1
14.6
11.8
7.01
5.37
Lease right-of-use assets
10
16.5
15.9
10.7
8.03
5.77
8.15
Intangible assets
0
44.9
28.7
26.3
23.9
28.1
Long-term investments
31.1
Other non-current assets
1.09
26.3
23.9
33
20.2
22.6
18.2
16.7
Total assets
465
632
704
1,013
623
546
919
936
Accounts payable
13.5
8.85
8.95
11.9
11.6
10.7
9.62
36.2
Accrued liabilities
2.1
3.02
29.7
37
31.3
57.4
58.3
76.7
Deferred revenue
0
8.16
6.1
14.6
7.19
Short-term debt
1.46
Total current liabilities
32.6
60.4
95.6
135
121
144
154
288
Long-term debt
54.5
91.8
92.4
431
431
446
437
Lease liabilities
14.7
17.4
12.3
8.98
4.7
3.81
Other non-current liabilities
0.5
3.53
9.52
22.1
26.6
5.63
0.29
0.24
Total liabilities
87.6
156
596
1,878
1,868
1,889
2,377
3,013
Total debt
54.5
95.4
93.9
431
431
446
437
2,007
Paid-in capital
134
494
848
1,021
842
939
1,481
1,903
2,058
Retained earnings
-48.7
-179
-440
-889
-1,437
-1,918
-2,561
-3,096
-3,821
Treasury stock
-75
-275
-275
-275
-275
-323
Other comprehensive income
0.25
0.19
-0.13
-0.33
0.03
0.01
0.01
Shareholders' equity
85.9
315
408
57.9
-870
-1,255
-1,354
-1,468
-2,087
Minority interests
2.5
62.4
65.3
48.4
3.41
11.3
11.2
10.2
10.6
Total equity
88.3
377
474
106
-867
-1,243
-1,343
-1,458
-2,076
Total liabilities and equity
465
632
704
1,013
623
546
919
936
Shares outstanding
92.1
124
123
147
151
175
190
195
Cash flow statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-43.8
-169
-289
-505
-586
-485
-653
-543
-733
Depreciation and amortization
0.86
1.46
5.84
6.77
6.49
6.08
5.43
Stock-based compensation
1.84
6.07
21.4
58.5
99.5
91.6
109
95.8
133
Deferred income tax
0
0
0
Change in receivables
15.2
15.3
-2.97
-135
Change in inventory
0
0
-25.3
Change in payables
1.58
16.7
-4.66
-0.74
2.83
-0.35
2.78
1.51
26.6
Cash from operations
-40.5
-137
-254
-400
-498
-419
-528
-521
-446
Capital expenditures
-0.46
-2.18
-2.64
-7.52
-13.2
-4.82
-1.31
-0.93
-1.1
Purchases of investments
-213
-288
-590
-137
-29.7
-93.8
-28.2
Sales and maturities of investments
249
380
480
82.6
95
Cash from investing
-0.46
-21
-217
-53
-201
453
54
60.8
-24.5
Debt issued
4
1
Debt repaid
-1.1
0
-124
-20.5
0
-473
Stock issued
0.14
0.44
1.79
0
0
4.85
450
315
0
Share buybacks
-75
-200
0
0
0
-48.3
Dividends paid
-1.15
-1
Cash from financing
113
502
399
447
736
-13.1
452
748
359
Net change in cash
72
344
-72
-5.52
37.7
20.5
-22.2
289
-111
Free cash flow
-41
-139
-256
-407
-511
-424
-529
-522
-447
Interest paid
1.57
6.09
15.3
29.8
54.4
61.1
91.3
43.7
Income taxes paid
0
0
1.2
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $65.57 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
94.4%
Gross profit / revenue.
Operating margin
-69.8%
Operating income / revenue.
EBITDA margin
-69.1%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-97.0%
Net income / revenue.
FCF margin
-61.1%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-60.9%
Cash from operations / revenue.
Return on assets (ROA)
-56.8%
Net income / average total assets.
R&D / revenue
70.9%
Research and development expense / revenue.
SG&A / revenue
90.6%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
20.7%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.1%
Capital expenditures / revenue.
D&A / revenue
0.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
126.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
86.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
127.4%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
120.7%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
86.5%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
1.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
14.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
5.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
2.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
9.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
10.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.23x
Current assets / current liabilities.
Quick ratio
1.09x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.81x
(Cash + short-term investments) / current liabilities.
Debt / assets
217.9%
Total debt / total assets.
Liabilities / assets
305.9%
Total liabilities / total assets.
Net debt
$1.93B
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$3.53
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$3.64
Revenue / diluted weighted shares.
FCF per share
-$2.22
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.22
Cash from operations / diluted weighted shares.
Book value per share
-$12.88
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
18.0x
Market cap / revenue.
EV/Sales
20.7x
Enterprise value / revenue.
FCF yield
-3.4%
Free cash flow / market cap.
Earnings yield
-5.4%
Net income / market cap (the inverse of P/E).
Shareholder yield
1.6%
(Dividends paid + share buybacks) / market cap.
What was BridgeBio Pharma, Inc.'s revenue in fiscal 2025?
BridgeBio Pharma, Inc. reported revenue of $502.1M for fiscal 2025, 126.3% higher than the year before.
Was BridgeBio Pharma, Inc. profitable in fiscal 2025?
No. It reported a net loss of $724.9M.
How much free cash flow did BridgeBio Pharma, Inc. generate in fiscal 2025?
Cash from operations of $445.9M minus capital expenditures of $1.1M left free cash flow of -$447.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.